Changing what’s possible
for People living with T cell-driven autoimmune disease

DELIVERING siRNA, ONLY TO T CELLS

Selective delivery of siRNA to T cells enables modulation of the specific T cell sub-types that drive disease pathology with sequence-level specificity and greater pharmacologic control.

siRNA delivery to T cells has historically been limited by the inability to selectively target T cells, while maintaining efficient release of siRNA into the cytoplasm.

Delivering siRNA with our T cell specific cell-targeted lipid nanoparticle (ctLNP) could silence disease-driving genes in T cells with genetic precision, potently blocking their function while sparing the broader immune system.

circle background

THE POWER OF CHANGING T CELL BEHAVIOR IN VIVO

T cells are master regulators of the immune system, and they are at the heart of tissue damage in a number of autoimmune diseases. Autoreactive T cells have a role in breaking tolerance and directly drive inflammation and tissue destruction.

By changing the activity of T cells, our targets can change how T cells activate, differentiate, migrate, and damage tissues.

Using our redosable ctLNP delivery system to selectively target T cells in vivo may open a broad indication space of T cell-driven autoimmune diseases.

circle background

Our unique delivery unlocks T CELL access for siRNA therapeutics

Delivery of siRNA to T cells requires receptor-selective targeting and endosomal escape –  our unique ctLNP delivery technology accomplishes both for the first time.

These features unlock a  broad landscape of targets to address T cell-driven autoimmune diseases, including targets that have been impossible to drug with other modalities.

We are prioritizing T cell-driven autoimmune indications based on severity and unmet need, on achieving rapid clinical proof of concept with a clear clinical and regulatory pathway, and on the degree of differentiation for our approach.

Leadership Team

GEOFF MCDONOUGH
President & Chief Executive Officer
Yalonda Howzef
Chief Legal Officer
ANTOINETTE PAONE
Chief Operating Officer
Kevin Conway
Chief Financial Officer
PHILLIP SAMAYOA
Chief Scientific Officer
Jasmin Tower
Chief HR Officer
Caitlin Cooper
SVP, Head of Business Development

Board of Directors

Scientific Advisory Board

News

Keep up to date with our latest news.

Join Us

We are always looking for those who are ready to share their vision, talent, and tenacity—who believe in our mission and themselves.

Scroll to Top